Adare Pharmaceuticals, Inc.

Quick facts

Phase 3 pipeline

• APT-1011 · Drug delivery / Multiple therapeutic areas
  APT-1011 is a permeation enhancer designed to improve the oral bioavailability of poorly absorbed drugs by modulating intestinal tight junctions.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Adare Pharmaceuticals, Inc. portfolio CI brief
• Adare Pharmaceuticals, Inc. pipeline updates RSS